Diabetes & Metabolism Journal

Original Article

Clinical Care/Education
Glycemic Effects of Rebaudioside A and Erythritol in People with Glucose Intolerance: Dong Hee Shin, Ji Hye Lee, Myung Shin Kang, Tae Hoon Kim, Su Jin Jeong, Chong Hwa Kim, Sang Soo Kim, In Joo Kim; Diabetes Metab J. 2016;40(4):283-289. Published online June 15, 2016; DOI: https://doi.org/10.4093/dmj.2016.40.4.283

5,763 View
49 Download
19 Web of Science
20 Crossref

Background

Rebaudioside A and erythritol are nonnutritive sweeteners. There have been several studies of their glycemic effects, but the outcomes remain controversial. The purpose of this study was to evaluate the glycemic effects of rebaudioside A and erythritol as a sweetener in people with glucose intolerance.

Methods

This trial evaluated the glycemic effect after 2 weeks of consumption of rebaudioside A and erythritol as sweeteners in a pre-diabetic population. The patients were evaluated for fructosamine, fasting plasma glucose, C-peptide, insulin, and 2-hour plasma glucose before and after consumption of sweetener. The primary outcome was a change in fructosamine levels from the baseline to the end of treatment. Secondary outcomes were the changes in levels of fasting plasma glucose and 2-hour plasma glucose.

Results

From the baseline to the end of experiment, the changes in fructosamine levels after consumption of rebaudioside A and erythritol, did not differ significantly (244.00±19.57 vs. 241.68±23.39 µmol/L, P=0.366). The change in levels from the baseline to end of the study for rebaudioside A and erythritol were fasting plasma glucose (102.56±10.72 vs. 101.32±9.20 mg/dL), 2-hour plasma glucose (154.92±54.53 vs. 141.92±42.22 mg/dL), insulin (7.56±4.29 vs. 7.20±5.12 IU/mL), and C-peptide (2.92±1.61 vs. 2.73±1.31 ng/mL), respectively, and also did not differ significantly (P>0.05 for all).

Conclusion

Our study suggests that consumption of rebaudioside A and erythritol does not alter the glucose homeostasis in people with glucose intolerance.

Citations

Citations to this article as recorded by

The Cardiometabolic Impact of Rebaudioside A Exposure during the Reproductive Stage
Isabella Bracchi, Juliana Morais, João Coelho, Ana Ferreira, Inês Alves, Cláudia Mendes, Beatriz Correia, Alexandre Gonçalves, João Guimarães, Inês Falcão-Pires, Elisa Keating, Rita Negrão
Biology.2024; 13(3): 163. CrossRef
Effect of stevia on blood glucose and HbA1C: A meta-analysis
Marzieh Zare, Mobina Zeinalabedini, Soraiya Ebrahimpour-Koujan, Nick Bellissimo, Leila Azadbakht
Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2024; 18(7): 103092. CrossRef
Re‐evaluation of erythritol (E 968) as a food additive
Maged Younes, Gabriele Aquilina, Laurence Castle, Gisela Degen, Karl‐Heinz Engel, Paul J. Fowler, Maria José Frutos Fernandez, Peter Fürst, Ursula Gundert‐Remy, Rainer Gürtler, Trine Husøy, Melania Manco, Wim Mennes, Peter Moldeus, Sabina Passamonti, Romi
EFSA Journal.2023;[Epub] CrossRef
Sugar-Free Dark Chocolate Consumption Results in Lower Blood Glucose in Adults With Diabetes
Barbara Oliveira, Kaja Falkenhain, Jonathan P Little
Nutrition and Metabolic Insights.2022; 15: 117863882210769. CrossRef
Acute responses of stevia and d-tagatose intake on metabolic parameters and appetite/satiety in insulin resistance
Verónica Sambra, Isabella A. Vicuña, Kathleen M. Priken, Selva L. Luna, Daniela A. Allendes, Paula M. Godoy, Victoria Novik, Claudia A. Vega
Clinical Nutrition ESPEN.2022; 49: 217. CrossRef
Modulating effects of steviol and steviol glycosides on adipogenesis, lipogenesis, glucose uptake and insulin resistance in 3T3-L1 adipocyte model
Jakub Michał Kurek, Joanna Zielińska-Wasielica, Katarzyna Kowalska, Zbigniew Krejpcio, Anna Olejnik
Journal of Functional Foods.2022; 94: 105141. CrossRef
Stevia, sucralose and sucrose added to a maqui-Citrus beverage and their effects on glycemic response in overweight subjects: A randomized clinical trial
Débora Villaño, Hedyeh Masoodi, Javier Marhuenda, Cristina García-Viguera, Pilar Zafrilla
LWT.2021; 144: 111173. CrossRef
Low-energy sweeteners and body weight: a citation network analysis
Mie Normand, Christian Ritz, David Mela, Anne Raben
BMJ Nutrition, Prevention & Health.2021; 4(1): 319. CrossRef
Diabetes and COVID-19, potentialities of Morus alba L. (mulberry) and Stevia rebaudiana Bertoni (stevia). Mini-review
Hernandez Claudia Chavez, Payrol Juan Abreu, Laime Sirley Gonzalez, Garcia Ariel Martinez, Michel Lazaro, Legarreta Morera, Perez Marisol Gonzalez
Global Journal of Rare Diseases.2021; : 006. CrossRef
Evaluation of minor steviol glycosides effect on insulin resistance, serum triglycerides, and antioxidant capacity of diabetised Wistar rats
Carolina Díaz Canul, Fibi Yenisie Coop Gamas, María Luisa Ávila Escalante, David Betancur-Ancona, Irma Aranda-González
International Food Research Journal.2021; 28(2): 342. CrossRef
Effects of the Daily Consumption of Stevia on Glucose Homeostasis, Body Weight, and Energy Intake: A Randomised Open-Label 12-Week Trial in Healthy Adults
Nikoleta S. Stamataki, Benjamin Crooks, Abubaker Ahmed, John T. McLaughlin
Nutrients.2020; 12(10): 3049. CrossRef
Safety of a proposed amendment of the specifications for steviol glycosides (E 960) as a food additive: to expand the list of steviol glycosides to all those identified in the leaves of Stevia Rebaudiana Bertoni
Maged Younes, Gabriele Aquilina, Karl‐Heinz Engel, Paul Fowler, Maria Jose Frutos Fernandez, Peter Fürst, Rainer Gürtler, Ursula Gundert‐Remy, Trine Husøy, Melania Manco, Wim Mennes, Peter Moldeus, Sabina Passamonti, Romina Shah, Ine Waalkens‐Berendsen, D
EFSA Journal.2020;[Epub] CrossRef
A comparison of the effects of Stevia extract and metformin on metabolic syndrome indices in rats fed with a high‐fat, high‐sucrose diet
Tahereh Ranjbar, Ali Akbar Nekooeian, Nader Tanideh, Omid Koohi‐Hosseinabadi, Seyed Jalil Masoumi, Sasan Amanat, Negar Azarpira, Ahmad Monabati
Journal of Food Biochemistry.2020;[Epub] CrossRef
The effect of a new mixture of sugar and sugar-alcohols compared to sucrose and glucose on blood glucose increase and the possible adverse reactions: A phase I double-blind, three-way randomized cross-over clinical trial
Mohammad Ali Mohsenpour, Fatemeh Kaseb, Reza Nazemian, Hassan Mozaffari-Khosravi, Hossein Fallahzadeh, Amin Salehi-Abargouei
Endocrinología, Diabetes y Nutrición.2019; 66(10): 647. CrossRef
Effect of Steviol Glycosides on Human Health with Emphasis on Type 2 Diabetic Biomarkers: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Camilla Christine Bundgaard Anker, Shamaila Rafiq, Per Bendix Jeppesen
Nutrients.2019; 11(9): 1965. CrossRef
The effect of a new mixture of sugar and sugar-alcohols compared to sucrose and glucose on blood glucose increase and the possible adverse reactions: A phase I double-blind, three-way randomized cross-over clinical trial
Mohammad Ali Mohsenpour, Fatemeh Kaseb, Reza Nazemian, Hassan Mozaffari-Khosravi, Hossein Fallahzadeh, Amin Salehi-Abargouei
Endocrinología, Diabetes y Nutrición (English ed.).2019; 66(10): 647. CrossRef
Non-nutritive Sweeteners and Glycaemic Control
Yoona Kim, Jennifer B. Keogh, Peter M. Clifton
Current Atherosclerosis Reports.2019;[Epub] CrossRef
FDA regulatory approach to steviol glycosides
Judith D. Perrier, Jeremy J. Mihalov, Susan J. Carlson
Food and Chemical Toxicology.2018; 122: 132. CrossRef
Health outcomes of non-nutritive sweeteners: analysis of the research landscape
Szimonetta Lohner, Ingrid Toews, Joerg J. Meerpohl
Nutrition Journal.2017;[Epub] CrossRef
Erythritol is a pentose-phosphate pathway metabolite and associated with adiposity gain in young adults
Katie C. Hootman, Jean-Pierre Trezzi, Lisa Kraemer, Lindsay S. Burwell, Xiangyi Dong, Kristin A. Guertin, Christian Jaeger, Patrick J. Stover, Karsten Hiller, Patricia A. Cassano
Proceedings of the National Academy of Sciences.2017;[Epub] CrossRef

Case Reports

A Case of Necrobiosis Lipoidica at the Insulin Injection Site in a Patient with Type 2 Diabetes Mellitus.: Woo Tae Kim, Tae Hoon Kim, Se Min Lee, Kang Hyun Choi, Seung Hyun Ko, Yu Bai Ahn, Ki Ho Song, Ho Young Son, Kyung Moon Kim, Si Young Kim; Korean Diabetes J. 2004;28(5):452-457. Published online October 1, 2004

1,170 View
18 Download

Abstract PDF: Nearly one third of patients with diabetes mellitus have some kinds of dermatologic complication. Necrobiosis lipoidica (NL) is a rare degenerative disease of the collagen in the dermis occurring in 0.3~0.7% of the diabetic population. This is a dermatologic condition presenting plaques that have an erythematous, violaceous border and yellowish atrophic center with telangiectasis on its surface. One third of these lesions may progress to ulcer if exposed to any trauma. There is some controversy regarding the degree of association between NL and diabetes mellitus. Necrobiosis lipoidica is commonly seen in patients with type 1 diabetes, but 7~30% of diabetic patients with NL have type 2 diabetes. We report a case of 54 year-old woman with 25 years of diabetic history. Her skin lesion was oval or irregular indurated plaques with central atrophy occurring both arm, lower abdomen and both anterior thigh, especially at insulin injecton site. We focused glycemic control as a treatment and used antiplatelet agents such as aspirin and cilostazol on the basis of microangiopathic athophysiology, combined with antibiotics. We need to inspect more closely any of skin lesions in diabetic patients, thus misdiagnosis and improper treatment should be reduced.

A Case of Invasive Aspergillosis of the Nasal Septum in a Patient with Diabetes Mellitus.: Tae Hoon Kim, Ji Sung Yoon, Ji O Mok, Yeo Joo Kim, Hyeong Kyu Park, Chul Hee Kim, Sang Jin Kim, Dong Won Byun, Kyo Il Suh, Myung Hi Yoo, Jang Mook Kim, Yoon Jung Kim; Korean Diabetes J. 2003;27(4):373-378. Published online August 1, 2003

1,341 View
18 Download

Abstract PDF: Invasive aspergillosis of the nasal cavity and paranasal sinuses is characterized by invasion and destruction of the bony sinus walls, the orbit, and other soft tissues of the face. It occurs particularly in patients with severe immune deficits, and less frequently in patients with diabetes mellitus. The therapeutic outcome of invasive aspergillosis is unsatisfactory. Mortality rates range from 50 to 80%, depending primarily on the underlying disease. In general, the prognosis depends on making a prompt diagnosis of infection and providing early treatment. However the diagnosis of invasive aspergillosis is difficult because there is no specific symptom, nor any rapid diagnostic method for confirmation. We report a case of a 64-year old woman with diabetes mellitus and invasive aspergillosis of the nasal septum. She was diagnosed by biopsy of the nasal septum and treated with systemic antifungal agent and surgical debridement. (Ed- paragraphs combined here) In conjunction with this case we review the previous literatures and suggest that prompt antifungal therapy with glycemic control is an important element in the treatment of invasive aspergillosis in a diabetic patient.

First
Prev
Page of 1
Next
Last

Search